Key result
In a mouse model, diabetes, but not experimental myocardial infarction, accelerated atherosclerotic lesion progression via monocyte-dependent necrotic core expansion.
Why the study?
Diabetes increases the risk of recurrent MI, and experimental MI can accelerate atherosclerosis via monocytosis, prompting investigation into whether diabetes and experimental MI synergize to accelerate atherosclerosis.
Does experimental myocardial infarction accelerate atherosclerosis in a mouse model of type 1 diabetes?
Does experimental myocardial infarction accelerate atherosclerosis in a mouse model of type 1 diabetes?
In a mouse model, diabetes rather than a prior myocardial infarction drives the acceleration of atherosclerotic lesion progression, suggesting recurrent MI risk in diabetes relates to higher baseline burden rather than MI-induced pathology.
Answers are grounded in this paper and cite their sources.
Diabetes may drive recurrent events via baseline burden, not post-MI effects, in mice; hypothesis-generating for human translation.
In addition to increasing the risk of an initial myocardial infarction (MI), diabetes increases the risk of a recurrent MI. Previous work suggests that an experimental MI can accelerate atherosclerosis via monocytosis. To test whether diabetes and experimental MI synergize to accelerate atherosclerosis, we performed ligation of the left anterior descending coronary artery to induce experimental MI or sham surgery in nondiabetic and diabetic mice with preexisting atherosclerosis. All mice subjected to experimental MI had significantly reduced left ventricular function. In our model, in comparisons with nondiabetic sham mice, neither diabetes nor MI resulted in monocytosis. Neither diabetes nor MI led to increased atherosclerotic lesion size, but diabetes accelerated lesion progression, exemplified by necrotic core expansion. The necrotic core expansion was dependent on monocyte recruitment, as mice with myeloid cells deficient in the adhesion molecule integrin α4 were protected from necrotic core expansion. In summary, diabetes, but not MI, accelerates lesion progression, suggesting that the increased risk of recurrent MI in diabetes is due to a higher lesional burden and/or elevated risk factors rather than the acceleration of the underlying pathology from a previous MI.
No takes yet. Share an insight, caveat, or question.
Kramer et al. (2020) studied Type 1 Diabetes and Myocardial Infarction. Experimental myocardial infarction (LAD ligation) and diabetes vs. Sham surgery and nondiabetic mice was evaluated on Atherosclerotic lesion size, lesion progression (necrotic core expansion), and monocytosis. In a mouse model, diabetes, but not experimental myocardial infarction, accelerated atherosclerotic lesion progression via monocyte-dependent necrotic core expansion.
Synapse has enriched 10 related papers. Consider them for comparative context: